The Prognostic Value of Anion Gap in Predicting Major Adverse Cardiovascular Events Among Patients With ST-Segment Elevation Myocardial Infarction

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06586424

Acronym

ANGIO-STEMI

Enrollment

Registered

2024-09-19

Start date

2024-01-01

Completion date

2024-10-05

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment Elevation Myocardial Infarction (STEMI)

Keywords

anion gap, major adverse cardiovascular events, st-segment elevation myocardial infarction

Brief summary

This study aims to evaluate the prognostic value of the anion gap in predicting major adverse cardiovascular events among patients with ST-segment elevation myocardial infarction. Researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as ST-segment elevation myocardial infarction and underwent primary percutaneous coronary intervention. The data consist of demographic data, clinical presentation, laboratory, and angiography result were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.

Interventions

DIAGNOSTIC_TESTAnion gap

Patient was taken blood examination before PPCI

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Adults with 18 - 70 years old with diagnosis of STEMI who underwent PPCI

Exclusion criteria

* History of heart failure due to any causes * Cardiogenic shock before PPCI * Any infection at the time of presentation * Pregnant woman * Other causes of high anion gap levels such as chronic kidney disease, metabolic acidosis, etc

Design outcomes

Primary

Measure	Time frame
Major Adverse Cardiovascular Events (MACE)	During hospitalization, up to 1 weeks

Secondary

Measure	Time frame
Incidence of reinfarction	During hospitalization, up to 1 weeks
Incidence of stroke	During hospitalization, up to 1 weeks
Incidence of mortality	During hospitalization, up to 1 weeks
Incidence of acute lung oedema	During hospitalization, up to 1 weeks
Incidence of cardiogenic shock	During hospitalization, up to 1 weeks
Incidence of lethal arrhythmia	During hospitalization, up to 1 weeks

Countries

Indonesia

Contacts

Primary ContactLeo Deddy Pradipta

dancingdeagle@gmail.com+6281316499074

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026